| Literature DB >> 35563236 |
Nicole Pochert1,2, Mariella Schneider1, Nadine Ansorge1, Annamarie Strieder1, Jacqueline Sagasser1, Matthias Reiger2, Claudia Traidl-Hoffmann2, Avidan Neumann2, Udo Jeschke1, Christian Dannecker1, Thorsten Kühn3, Nina Ditsch1.
Abstract
Seroma development after breast cancer surgery is the most common postoperative complication seen after mastectomy but neither its origin nor its cellular composition is known. To investigate the assumption of immunological significance, one of the first aims of this pilot study is to describe the cellular content of collected seroma fluids and its corresponding serum in patients with simple mastectomy after needle aspiration, as well as the serum of healthy controls. The content of red blood cells (RBC) was measured by haemato-counter analyses, and the lymphocyte identification/quantification was conducted by flow cytometry analyses in seroma fluid (SFl) and the sera of patients (PBp) as well as controls (PBc). Significantly lower numbers of RBCs were measured in SFl. Cytotoxic T cells are significantly reduced in SFl, whereas T helper (Th) cells are significantly enriched compared to PBp. Significantly higher numbers of Th2 cells were found in SFl and PBp compared to PBc. The exact same pattern is seen when analyzing the Th17 subgroup. In conclusion, in contrast to healthy controls, significantly higher Th2 and Th17 cell subgroup-mediated immune responses were measured in seroma formations and were further confirmed in the peripheral blood of breast cancer (including DCIS) patients after simple mastectomy. This could lead to the assumption of a possible immunological cause for the origin of a seroma.Entities:
Keywords: T-helper cells; Th17 cells; Th2 cells; breast cancer; lymphocyte enrichment; seroma formation; simple mastectomy
Mesh:
Year: 2022 PMID: 35563236 PMCID: PMC9101279 DOI: 10.3390/ijms23094848
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Description of tumor characteristics of 16 patients and 18 tumors (2 contralateral).
| Tumor Characteristics | Subgroups | n (Number) |
|---|---|---|
| Histopathological type | ||
| NST | 11 | |
| Focality | ||
| unifocal | 12 | |
| Hormone receptor status | ||
| HR + | 14 | |
| Her-2/neu | ||
| positive | 2 | |
| Ki67 | ||
| <20% | 8 | |
| Tumor size | ||
| ypT0 | 3 | |
| Axillary nodal status | ||
| (y)pN0 | 12 | |
| Grading | ||
| G1 | 2 |
Figure 1Cell composition of seroma fluid (SFl) and peripheral blood of patients (PBp) and controls (PBc) by flow cytometry analysis or automated cell counting. (A) Total cell count of RBCs in SFl and PBp/c determined by automated cell counting (Sysmex). (B) Percentage of CD45+ leucocytes in relation to all cells recorded. (C) Gating strategy of granulocytes (Granulo), monocytes (Mono), and lymphocytes (Lymph) in SFl and PBp after staining with panel 1; debris was excluded by size discrimination. (D) Percentages of granulocytes, monocytes, and lymphocytes within the CD45+ cell population; ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Description of antibody panels used for flow cytometry analysis.
| Panel 1 (all Beckman Coulter) | Fluorescent Label |
|---|---|
| anti-human CD45 antibody | Chromium Orange |
| anti-human CD3 antibody | APC-AF750 |
| anti-human CD19 antibody | ECD |
| anti-human CD4 antibody | APC |
| anti-human CD8 antibody | Pacific Blue |
| anti-human CD16 antibody | PE |
| anti-human CD56 antibody | PE |
| anti-human HLA-DR antibody | PC7 |
| anti-human CD4 antibody | VioBlue |
| anti-human CD183 (CXCR3) antibody | VioBright FITC |
| anti-human CD194 (CXCR4) antibody | PE-Vio 770 |
| anti-human CD196 (CCR6) antibody | PE |
| anti-human CCR10 antibody | APC |
| anti-human CD45 antibody | Chromium Orange |
| anti-human CD3 antibody | APC-AF750 |
| anti-human CD4 antibody | APC |
| anti-human CD127 antibody | FITC |
| anti-human CD25 antibody | PE |
| anti-human CD45RA antibody | ECD |
Figure 2Lymphocyte composition of SFl and PBp/c by flow cytometry analysis. (A) Gating strategy of lymphocyte subpopulations in SFl and PBp after staining with panel 1; CD3+ T cells are depicted in blue, CD19+ B cells are shown in red, and NK cells in green. (B) Percentage of lymphocytes for CD3+ T cells, CD19+ B cells, and CD56/16+ CD3- NK cells. (C) Percentage of lymphocytes for CD56/16+ CD3+ NKT cells and activated lymphocytes (HLA-DR+); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 3Cell composition of CD3+ T cells in SFl and PBp/c by flow cytometry analysis. (A) Gating strategy for the T cell subpopulations CD8+ cytotoxic T cells and CD4+ T helper cells in SFl and PBp after staining with panel 1. (B) Distribution of cytotoxic T cells and T helper cells within the T cell compartment. (C) Percentage of effector T helper cells within the CD4+ T helper cell compartment. (D) Gating strategy of regulatory T helper cell subpopulations (Treg) in SFl and PBp after staining with panel 3. (E) Percentage of Treg as well as the proportion of CD45RA+ (naïve) Treg within the T helper cell compartment. (F) Percentage of CD45RA+ (naïve) T helper cells; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 4Comparison of all leucocyte subpopulations between first and second fine-needle aspiration.